The Patent Finder

Terms ending in 2037

Araxes Pharma LLC

Every in-force patent on Araxes Pharma LLC's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 10,646,488Conjugates of Cereblon Binding Compounds and G12C Mutant Kras, Hras or Nras Protein Modulating Compounds and Methods of Use Thereof
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 10,280,172Inhibitors of Kras G12C Mutant Proteins
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 10,723,738Inhibitors of Kras G12C Mutant Proteins
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 10,377,743Inhibitors of Ras and Methods of Use Thereof
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited